Cash flow Bio-Techne Corporation

Equities

TECH

US09073M1045

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-01-22 pm EST			5-day change	1st Jan Change
78.71 ^USD	-0.05%		+5.33%	+9.27%

Jan. 14	Bio-Techne Corporation Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-14-2025 10:30 AM
Jan. 10	Bio-Techne Expands R&D Systems Ai-Engineered Designer Protein Portfolio to Advance Cell Therapy and Regenerative Medicine	CI

de2212b224f065fb9463413041c7e79.HmASrjwR-OB1agMKi2fQGo4H4SbDub_NoN-wZGBrTNc.Uw142Vt1k5UtD3lk1ACCc8RPpXGZ3dms0ZPAJRIyH5p8FCrLbUKcoxA5Ug

Published financial data: BIO-TECHNE CORPORATION

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: June	2020	2021	2022	2023	2024
Revenues	739M	931M	1.11B	1.14B	1.16B
Total Revenues	739M	931M	1.11B	1.14B	1.16B
Cost of Goods Sold, Total	255M	297M	348M	366M	389M
Gross Profit	483M	634M	758M	770M	770M
Selling General & Admin Expenses, Total	267M	318M	371M	397M	429M
R&D Expenses	65.19M	70.6M	87.14M	92.49M	96.66M
Other Operating Expenses, Total	332M	388M	459M	489M	525M
Operating Income	151M	246M	299M	281M	245M
Interest Expense, Total	-19.2M	-13.95M	-11.31M	-11.22M	-15.74M
Interest And Investment Income	605K	473K	794K	3.41M	3.32M
Net Interest Expenses	-18.59M	-13.48M	-10.52M	-7.8M	-12.41M
Income (Loss) On Equity Invest.	-	-	-	-1.14M	-6.84M
Currency Exchange Gains (Loss)	1.7M	-6.65M	699K	676K	-726K
Other Non Operating Income (Expenses)	-1.18M	-570K	-198K	-523K	-716K
EBT, Excl. Unusual Items	133M	225M	289M	272M	225M
Restructuring Charges	-87K	-142K	-1.64M	-3.83M	-8.9M
Merger & Related Restructuring Charges	-1.7M	-3.74M	-3.29M	8.75M	-8.29M
Gain (Loss) On Sale Of Investments	138M	-68.05M	15.19M	49.33M	283K
Asset Writedown	-	-	-18.72M	-	-21.96M
Legal Settlements	7.16M	-	-	-	-3.51M
Other Unusual Items	905K	-5.3M	20.4M	12.1M	3.5M
EBT, Incl. Unusual Items	276M	148M	301M	339M	186M
Income Tax Expense	47.18M	8.59M	38.29M	53.22M	17.58M
Earnings From Continuing Operations	229M	140M	263M	285M	168M
Net Income to Company	229M	140M	263M	285M	168M
Minority Interest	-	825K	8.95M	-179K	-
Net Income - (IS)	229M	140M	272M	285M	168M
Preferred Dividend and Other Adjustments	224K	86K	121K	70K	33K
Net Income to Common Incl Extra Items	229M	140M	272M	285M	168M
Net Income to Common Excl. Extra Items	229M	140M	272M	285M	168M
Per Share Items
Net EPS - Basic	1.5	0.91	1.73	1.81	1.07
Basic EPS - Continuing Operations	1.5	0.91	1.73	1.81	1.07
Basic Weighted Average Shares Outstanding	153M	155M	157M	157M	158M
Net EPS - Diluted	1.46	0.87	1.66	1.76	1.05
Diluted EPS - Continuing Operations	1.46	0.87	1.66	1.76	1.05
Diluted Weighted Average Shares Outstanding	158M	162M	164M	162M	161M
Normalized Basic EPS	0.54	0.91	1.21	1.08	0.89
Normalized Diluted EPS	0.53	0.88	1.16	1.05	0.87
Dividend Per Share	0.32	0.32	0.32	0.32	0.32
Payout Ratio	21.33	35.34	18.45	17.63	29.99
American Depositary Receipts Ratio (ADR)	0.03	0.03	0.03	0.03	0.03
Supplemental Items
EBITDA	199M	297M	360M	344M	310M
EBITA	177M	275M	332M	313M	277M
EBIT	151M	246M	299M	281M	245M
EBITDAR	215M	333M	379M	364M	334M
Effective Tax Rate - (Ratio)	17.06	5.8	12.7	15.71	9.47
Current Domestic Taxes	24.99M	21.86M	16.74M	72.56M	45.08M
Current Foreign Taxes	8.58M	14.74M	14.48M	10.45M	12.66M
Total Current Taxes	33.57M	36.6M	31.22M	83.02M	57.74M
Deferred Domestic Taxes	16.13M	-25.77M	9.61M	-31.24M	-32.86M
Deferred Foreign Taxes	-2.52M	-2.24M	-2.54M	1.44M	-7.3M
Total Deferred Taxes	13.61M	-28.01M	7.06M	-29.8M	-40.16M
Normalized Net Income	82.93M	142M	190M	170M	140M
Interest on Long-Term Debt	19.2M	-	-	-	-
Supplemental Operating Expense Items
Advertising Expense	4.2M	4.7M	4.6M	4.8M	4.1M
Research And Development Expense From Footnotes	99.69M	107M	128M	137M	143M
Net Rental Expense, Total	16.4M	36.1M	18.7M	20.3M	23.2M
Imputed Operating Lease Interest Expense	5.2M	9.16M	4.48M	4.66M	6.68M
Imputed Operating Lease Depreciation	11.2M	26.94M	14.22M	15.64M	16.52M
Stock-Based Comp., COGS (Total)	1.6M	-	1.4M	1M	900K
Stock-Based Comp., SG&A Exp. (Total)	32.67M	50.2M	45.08M	40.27M	39.45M
Stock-Based Comp., Other (Total)	-	-	-	-	-
Total Stock-Based Compensation	34.27M	50.2M	46.48M	41.27M	40.35M

Fiscal Period: June	2020	2021	2022	2023	2024
Assets
Cash And Equivalents	147M	199M	173M	181M	152M
Short Term Investments	124M	32.46M	74.46M	23.74M	1.07M
Total Cash And Short Term Investments	271M	232M	247M	204M	153M
Accounts Receivable, Total	123M	145M	195M	218M	241M
Total Receivables	123M	145M	195M	218M	241M
Inventory	103M	117M	141M	172M	180M
Deferred Tax Assets Current	-	-	-	-	-
Other Current Assets, Total	24.34M	16.92M	22.86M	27.07M	43.43M
Total Current Assets	521M	511M	606M	621M	617M
Gross Property Plant And Equipment	418M	472M	500M	558M	599M
Accumulated Depreciation	-170M	-190M	-211M	-234M	-257M
Net Property Plant And Equipment	248M	282M	289M	325M	342M
Long-term Investments	-	275K	11.03M	273M	252M
Goodwill	728M	843M	822M	873M	973M
Other Intangibles, Total	517M	616M	532M	535M	507M
Other Long-Term Assets, Total	13.52M	11.3M	35.8M	12.59M	12.12M
Total Assets	2.03B	2.26B	2.29B	2.64B	2.7B
Liabilities
Accounts Payable, Total	23.09M	29.38M	33.86M	25.68M	37.97M
Accrued Expenses, Total	40.18M	66.58M	79.84M	51.63M	74.7M
Current Portion of Long-Term Debt	12.5M	13.28M	12.98M	-	-
Current Portion of Leases	9.54M	11.6M	11.93M	11.2M	12.92M
Current Income Taxes Payable	2.38M	5.34M	13.24M	12.02M	3.71M
Unearned Revenue Current, Total	13.05M	19M	23.41M	23.07M	27.93M
Other Current Liabilities	5.94M	7.12M	767K	4.91M	2.15M
Total Current Liabilities	107M	152M	176M	129M	159M
Long-Term Debt	362M	336M	243M	350M	319M
Long-Term Leases	67.25M	67.62M	58.13M	93.77M	87.62M
Unearned Revenue Non Current	1.15M	1M	2.09M	1.53M	2.27M
Deferred Tax Liability Non Current	101M	93.12M	98.99M	88.98M	55.86M
Other Non Current Liabilities	8.67M	41.26M	15.14M	9.39M	10.89M
Total Liabilities	646M	692M	594M	672M	635M
Common Stock, Total	385K	390K	392K	1.58M	1.58M
Additional Paid In Capital	421M	534M	654M	722M	820M
Retained Earnings	1.06B	1.09B	1.12B	1.31B	1.33B
Comprehensive Income and Other	-97.2M	-57.29M	-75.2M	-66.06M	-78.32M
Total Common Equity	1.38B	1.56B	1.7B	1.97B	2.07B
Minority Interest	-	8.26M	-759K	-	-
Total Equity	1.38B	1.57B	1.7B	1.97B	2.07B
Total Liabilities And Equity	2.03B	2.26B	2.29B	2.64B	2.7B
Supplemental Items
ECS Total Shares Outstanding on Filing Date	154M	156M	157M	158M	159M
ECS Total Common Shares Outstanding	154M	156M	157M	158M	158M
Book Value / Share	8.98	10.03	10.86	12.47	13.08
Tangible Book Value	136M	104M	348M	559M	589M
Tangible Book Value Per Share	0.89	0.67	2.22	3.55	3.72
Total Debt	451M	429M	326M	455M	420M
Net Debt	180M	197M	79.42M	251M	267M
Debt Equivalent Oper. Leases	131M	289M	150M	162M	186M
Minority Interest, Total (Incl. Fin. Div)	-	8.26M	-759K	-	-
Equity Method Investments, Total	-	-	-	256M	242M
Account Code - Inventory Valuation	5	5	5	5	5
Inventories - Raw Materials, Total	51.53M	55.1M	79.29M	84.55M	79.38M
Inventories - Finished Goods, Total	51.62M	61.65M	61.83M	87.09M	100M
Land - (BS)	8.52M	8.61M	8.57M	9.1M	8.15M
Buildings, Total	184M	191M	230M	245M	244M
Machinery, Total	154M	198M	175M	190M	216M
Full Time Employees	2.3K	2.6K	3K	3.05K	3.1K
Accumulated Allowance for Doubtful Accounts (Supple)	775K	1.23M	2.57M	4.74M	4.39M

Fiscal Period: June	2020	2021	2022	2023	2024
Net Income	229M	140M	272M	285M	168M
Depreciation & Amortization - CF	21.87M	22.81M	28.02M	30.82M	33.39M
Amortization of Goodwill and Intangible Assets - (CF)	26.36M	28.44M	32.45M	32.11M	31.72M
Depreciation & Amortization, Total	48.24M	51.25M	60.47M	62.94M	65.11M
Amortization of Deferred Charges, Total - (CF)	34.5M	36.5M	40.6M	44.3M	46.6M
(Gain) Loss From Sale Of Asset	-	-	-	-11.68M	21.96M
(Gain) Loss on Sale of Investments - (CF)	-138M	67.88M	-15M	-37.65M	-283K
Asset Writedown & Restructuring Costs	-	-	19.26M	-	2.63M
(Income) Loss On Equity Investments - (CF)	-	-	-	1.14M	6.84M
Stock-Based Compensation (CF)	32.37M	48.98M	42.18M	39.23M	38.04M
Tax Benefit from Stock Options	-	-	-	-	-
Other Operating Activities, Total	3.59M	-22.12M	-24.77M	-38.57M	-39.93M
Change In Accounts Receivable	6.56M	-15.55M	-57.6M	-20.87M	-20.53M
Change In Inventories	-14.86M	-7.14M	-32.01M	-30.17M	-14.22M
Change In Accounts Payable	10.34M	19.09M	12.74M	-7.91M	25.77M
Change In Income Taxes	-7.23M	13.43M	2.67M	-2.49M	-10.6M
Change in Other Net Operating Assets	-53K	19.44M	4.68M	-29.14M	9.47M
Cash from Operations	205M	352M	325M	254M	299M
Capital Expenditure	-51.74M	-44.3M	-44.91M	-38.24M	-62.88M
Cash Acquisitions	-	-225M	-	-101M	-170M
Divestitures	-	-	-	17.82M	-
Investment in Marketable and Equity Securities, Total	78.84M	26.14M	-26.94M	-144M	29.55M
Other Investing Activities, Total	-	-	-25M	-	-
Cash from Investing	27.1M	-244M	-96.85M	-266M	-203M
Long-Term Debt Issued, Total	40M	256M	90M	620M	225M
Total Debt Issued	40M	256M	90M	620M	225M
Long-Term Debt Repaid, Total	-188M	-272M	-176M	-526M	-256M
Total Debt Repaid	-188M	-272M	-176M	-526M	-256M
Issuance of Common Stock	70.98M	65.09M	77.16M	29.81M	60.94M
Repurchase of Common Stock	-50.11M	-43.18M	-184M	-48.46M	-102M
Common Dividends Paid	-48.9M	-49.62M	-50.18M	-50.28M	-50.42M
Common & Preferred Stock Dividends Paid	-48.9M	-49.62M	-50.18M	-50.28M	-50.42M
Other Financing Activities, Total	-7.27M	-19.34M	88K	-2.46M	-
Cash from Financing	-184M	-62.55M	-243M	22.62M	-122M
Foreign Exchange Rate Adjustments	-2.77M	6.37M	-12.09M	-3.36M	-2.33M
Net Change in Cash	45.74M	52.47M	-26.52M	8M	-28.78M
Supplemental Items
Cash Interest Paid	18.62M	13.58M	11.03M	8.37M	14.5M
Cash Income Tax Paid (Refund)	41.99M	20.95M	30.34M	88.43M	65.25M
Levered Free Cash Flow	139M	252M	227M	186M	214M
Unlevered Free Cash Flow	151M	261M	234M	194M	224M
Change In Net Working Capital	8.3M	-13.75M	55.77M	92.45M	18.24M
Net Debt Issued / Repaid	-148M	-15.5M	-85.5M	94M	-31M

Fiscal Period: June	2020	2021	2022	2023	2024
Profitability
Return on Assets	4.82	7.17	8.21	7.12	5.74
Return on Total Capital	5.36	8.03	9.29	7.9	6.24
Return On Equity %	18.01	9.46	16.08	15.57	8.33
Return on Common Equity	17.99	9.53	16.66	15.55	8.33
Margin Analysis
Gross Profit Margin %	65.41	68.14	68.57	67.76	66.47
SG&A Margin	36.18	34.12	33.6	34.89	36.97
EBITDA Margin %	26.94	31.94	32.56	30.27	26.78
EBITA Margin %	23.98	29.49	30.02	27.56	23.9
EBIT Margin %	20.41	26.43	27.09	24.73	21.16
Income From Continuing Operations Margin %	31.04	14.99	23.8	25.11	14.5
Net Income Margin %	31.04	15.08	24.61	25.1	14.5
Net Avail. For Common Margin %	31.01	15.07	24.6	25.09	14.5
Normalized Net Income Margin	11.23	15.22	17.17	14.96	12.11
Levered Free Cash Flow Margin	18.84	27.12	20.53	16.41	18.5
Unlevered Free Cash Flow Margin	20.47	28.06	21.17	17.02	19.35
Asset Turnover
Asset Turnover	0.38	0.43	0.49	0.46	0.43
Fixed Assets Turnover	3.67	3.51	3.88	3.71	3.48
Receivables Turnover (Average Receivables)	5.68	6.95	6.5	5.5	5.04
Inventory Turnover (Average Inventory)	2.63	2.7	2.7	2.34	2.21
Short Term Liquidity
Current Ratio	4.88	3.35	3.44	4.84	3.87
Quick Ratio	3.69	2.48	2.51	3.29	2.47
Operating Cash Flow to Current Liabilities	1.92	2.31	1.85	1.98	1.88
Days Sales Outstanding (Average Receivables)	64.41	52.52	56.11	66.31	72.61
Days Outstanding Inventory (Average Inventory)	139.1	135.3	135.43	155.75	165.46
Average Days Payable Outstanding	26.88	30.87	31.04	27.37	29.36
Cash Conversion Cycle (Average Days)	176.63	156.94	160.5	194.68	208.71
Long Term Solvency
Total Debt/Equity	32.64	27.3	19.19	23.14	20.28
Total Debt / Total Capital	24.61	21.44	16.1	18.79	16.86
LT Debt/Equity	31.05	25.72	17.73	22.57	19.65
Long-Term Debt / Total Capital	23.41	20.2	14.87	18.33	16.34
Total Liabilities / Total Assets	31.88	30.57	25.88	25.47	23.49
EBIT / Interest Expense	7.85	17.64	26.48	25.07	15.59
EBITDA / Interest Expense	11.22	23.9	33.48	32.49	21.2
(EBITDA - Capex) / Interest Expense	8.53	20.72	29.51	29.08